The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

BAM15

2-Fluorophenyl

C
Animal replicated
Research chemicalMitochondrial UncouplerSmall MoleculeProtonophore
RouteOralGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
N5,N6-bis(2-Fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine — Mitochondrial Uncoupler — Mitochondrial Uncoupler, Small Molecule, Protonophore.
Why people use it
Used primarily for weight loss and mitochondrial health.
If you only read one thing

BAM15 resolves DNP's central problem — it produces fat loss without hyperthermia in every mouse study conducted. The mechanism design is elegant: the pH-dependent self-limiting proton transport prevents the positive feedback loop that kills DNP users. The Nature Communications 2020 paper showed 30% fat mass reduction, no lean mass loss, no food intake change, no temperature elevation, no biochemical toxicity markers — a cleaner metabolic safety profile than any currently approved obesity drug. The problem: this was all in mice. No human being has ever taken BAM15 in a controlled clinical trial. The dose extrapolation from mouse to human has the same methodological limitations as 5-Amino-1MQ (IP vs oral route differences, metabolic rate scaling). Whether the pH-dependent self-limiting mechanism that prevents hyperthermia in mice will perform identically in humans — across the wide range of metabolic states, concurrent medications, and individual variation present in a human population — is unknown. This is the most mechanistically compelling fat loss compound in this reference and the one that requires the most patience.

Check interactions →
Published literature
0human trials0human studies3animal2in vitro

BAM15 itself has zero human clinical trials, no Phase 1 safety testing, no human pharmacokinetic data, and no human dose-response data.

Evidence reality check
Human evidence
No human studies
0 observational; RCT evidence not present in corpus.
Preclinical base
5 lab signals
3 animal; 2 in-vitro/mechanistic.
Risk posture
No major flags listed
Review route-specific cautions before use.
Categories
Weight Loss & MetabolicMitochondrial & Energy
Properties
Active malignancy: hard stopNot injectable
Evidence
CAnimal replicated
What Mitochondrial Uncoupling Means
The mitochondria's inner membrane normally maintains a proton gradient — more protons (H+) on the outside than inside. This gradient drives protons back through ATP synthase, powering ATP production (the process of oxidative phosphorylation). Mitochondrial uncouplers are lipophilic molecules that penetrate the IMM and carry protons across it independently of ATP synthase — 'uncoupling' fuel oxidation from ATP synthesis. The result: the cell must burn more substrate (fat, glucose) to maintain the proton gradient, but captures less of that energy as ATP. The energy difference is released as heat — increasing metabolic rate without increasing appetite or requiring exercise. This is the mechanism of endogenous uncoupling protein 1 (UCP1) in brown adipose tissue, which explains how cold exposure generates heat without shivering.
The Landmark Paper
Alexopoulos SJ, Chen SY, Brandon AE, et al. (2020). Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications. 11(1):2397. PMC7224297. doi:10.1038/s41467-020-16298-2. Key findings: orally bioavailable; dose-dependently increases nutrient oxidation; decreases body fat mass; does did not alter food intake; does did not alter lean body mass; does did not alter body temperature; no biochemical or haematological markers of toxicity; decreases hepatic fat; decreases inflammatory lipids; strong antioxidant effects; improves insulin sensitivity across multiple tissue types (hyperinsulinemic-euglycemic clamp).
Why BAM15 Doesn't Cause Hyperthermia
DNP causes hyperthermia because it is a non-selective protonophore — it carries protons proportionally to the concentration gradient, with no self-limiting mechanism. As body temperature rises, DNP activity increases further, producing a positive feedback loop that becomes lethal. BAM15's mechanism is pH-dependent and structurally self-limiting: the oxadiazolopyrazine scaffold creates a proton transport mechanism that decreases in activity at lower pH — which is precisely what happens locally when proton transport increases. This built-in negative feedback prevents the runaway thermogenesis that kills DNP users. In the mouse studies, body temperature was monitored continuously and showed no elevation at any effective anti-obesity dose. This is the single most important pharmacological distinction between BAM15 and DNP.
Human Evidence and Status
Zero human clinical trials as of mid-2026. BAM15 has not entered Phase 1 safety testing in humans. No human pharmacokinetic data. No human dose-response. All evidence is from mouse and in vitro studies. The compound with the most comparable mechanism to enter human testing is HU6 (a different mitochondrial uncoupler from Rivus Pharmaceuticals) which reached Phase 1/2 in 2024-2025 — establishing that the class can be advanced to human development, but BAM15 itself is not yet there.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
5-Amino-1MQ
C
Same class · Small Molecule

The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.

ATX-304
C
Same class · Small Molecule

Oral small-molecule pan-AMPK activator and mitochondrial uncoupler in active Phase 1b/2 clinical development. Formerly O-304, now ATX-304 under Amplifier Therapeutics / Cambrian Bio. Phase 2a human data show fasting glucose reduction in type 2 diabetes; obesity and cardiometabolic outcomes remain investigational.

Cardarine
C
Same class · Small Molecule

GlaxoSmithKline Halted Their Own Drug in 2007 Because It Caused Cancer in Every Animal Species They Tested. The Community Is Still Using It. The Drug Worked. That Is the Entire Problem.

Check interactions